X
Novo’s oral semaglutide on target in phase 3 trial
https://pharmaphorum.com/news/novos-oral-semaglutide-target-phase-3-trial/
semaglutide
FDA experts back Novo Nordisk’s key diabetes drug
Novo hopes for blockbuster sales from semaglutide
No cardio protection indication for Novo’s semaglutide – yet
Danish pharma plans outcome trial to confirm benefits in SUSTAIN 6
Novo’s semaglutide outperforms Lilly GLP-1 rival
If approved semaglutide could become set the standard for GLP-1 therapy
Semaglutide could transform diabetes treatment, revive Novo Nordisk revenues
Oral formulation of GLP-1 drug could help cut heart attacks, tackle liver and kidney problems
